ALUMIS INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ALMS in the last 7 days.
No SEC Form 4 filings for $ALMS in the last 30 days.
See all $ALMS insider activity →Alumis Inc. (ALMS) reported positive Phase 3 data for envudeucitinib, showing 54% PASI 100 response at Week 48. The therapy improved scalp clearance, itch relief, and quality of life. Alumis plans to submit an NDA in 4Q 2026. The treatment was well-tolerated with no new safety signals.
H.C. Wainwright reiterated a Buy rating and $15.00 price target on Alumis Inc (ALMS) after positive LATITUDE Atlas trial results for zaso. The stock trades at $6.85, down from its 52-week high. Analysts view the data favorably but note mixed reactions due to recent Phase 2b trial failures for Envudeucitinib.
On September 9, 2026, significant insider trading activity was reported. Alumis Inc. (ALMS) director acquired $10.7M in shares, while NVIDIA (NVDA) director sold $235.6M. Greenwave (GWAV) CEO bought $8M in shares, and BELITE BIO (BLTE) executives sold $31.9M. Workday (WDAY) director sold $17.9M in shares. Dell (DELL) insiders sold $48.1M. Inhibrx (INBX) and Cytosorbents (CTSO) directors also made notable purchases.
Recent ALMS coverage spans financial news, technology and market movers.
Positive Phase 3 results likely boost ALMS valuation ahead of NDA filing.
Positive trial data may drive the stock higher despite recent declines.
Net buying by insider may support ALMS price.
Positive Phase 2 data and insider buying suggest near‑term upside, but mixed lupus trial outcome adds risk.
The insider sale may signal limited confidence and could exert slight downward pressure.
AlphAI scores every news story that mentions ALMS with an AI model for sentiment and relevance, and aggregates insider trades from ALUMIS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alumis Inc. (ALMS) reported positive Phase 3 data for envudeucitinib, showing 54% PASI 100 response at Week 48. The therapy improved scalp clearance, itch relief, and quality of life. Alumis plans to submit an NDA in 4Q 2026. The treatment was well-tolerated with no new safety signals.
3 min readH.C. Wainwright reiterated a Buy rating and $15.00 price target on Alumis Inc (ALMS) after positive LATITUDE Atlas trial results for zaso. The stock trades at $6.85, down from its 52-week high. Analysts view the data favorably but note mixed reactions due to recent Phase 2b trial failures for Envudeucitinib.
3 min readOn September 9, 2026, significant insider trading activity was reported. Alumis Inc. (ALMS) director acquired $10.7M in shares, while NVIDIA (NVDA) director sold $235.6M. Greenwave (GWAV) CEO bought $8M in shares, and BELITE BIO (BLTE) executives sold $31.9M. Workday (WDAY) director sold $17.9M in shares. Dell (DELL) insiders sold $48.1M. Inhibrx (INBX) and Cytosorbents (CTSO) directors also made notable purchases.
3 min readAlumis (ALMS) stock rose 6.3% in pre-market trading after presenting long-term skin-clearance data for envudeucitinib at the Cantor Fitzgerald Global Healthcare Conference. Management highlighted potential partnerships and insider Srinivas Akkaraju bought 986,000 shares. The FDA application for envudeucitinib is expected in Q4 2026.
2 min readAKKARAJU SRINIVAS sold 96,131 indirectly-held shares of ALUMIS INC. (ALMS) at $10.55 ($1.01M total) across 2 trades on 2026-09-08.
1 min readAKKARAJU SRINIVAS purchased 986,721 indirectly-held shares of ALUMIS INC. (ALMS) at an average of $10.87 ($10.63–$11.17, $10.73M total) across 4 trades over 2026-09-04 to 2026-09-08.
1 min readAlumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet primary or secondary endpoints in the overall population. However, a prespecified subgroup with high interferon gene signature showed numerically higher responses. The company plans to discuss Phase 3 trial design with regulators. Envudeucitinib was generally well tolerated.
3 min readAlumis Inc. (ALMS) shares dropped 57% after its Phase 2b lupus study missed primary goals, though a patient subgroup showed promising results. The company plans to discuss a late-stage trial with regulators. Wells Fargo and Baird lowered price targets but maintained positive ratings. ALMS is down 3% year-to-date.
2 min readAlumis (ALMS) reported its Phase IIb LUMUS trial for envudeucitinib in lupus failed to meet primary and secondary endpoints, causing shares to drop 50%. The trial involved 408 patients and measured disease activity improvement over 48 weeks.
2 min readAlumis stock fell 54.2% in pre-market trading after its Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus missed primary and secondary endpoints. A subgroup of patients showed positive responses, but the overall trial population was under-represented. The company plans to discuss a Phase 3 program with regulators. The Nasdaq, S&P 500, and Dow Jones also declined, exacerbating the sell-off.
2 min read
